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Abstract 
As genetic association studies increase in size to 100,000s of individuals, subtle biases may 
influence conclusions. One possible bias is “index event bias” (IEB) that appears due to the 
stratification by, or enrichment for, disease status when testing associations between genetic 
variants and a disease-associated trait. We aimed to test the extent to which IEB influences 
some known trait associations in a range of study designs and provide a statistical framework 
for assessing future associations. Analysing data from 113,203 non-diabetic UK Biobank 
participants, we observed three (near TCF7L2, CDKN2AB and CDKAL1) overestimated 
(BMI-decreasing) and one (near MTNR1B) underestimated (BMI-increasing) associations 
among 11 type 2 diabetes risk alleles (at P<0.05). IEB became even stronger when we tested 
a type 2 diabetes genetic risk score composed of these 11 variants (-0.010 SDs BMI per 
allele, P=5x10
-4
), which was confirmed in four additional independent studies. Similar results 
emerged when examining the effect of blood pressure increasing alleles on BMI in 
normotensive UK Biobank samples. Furthermore, we demonstrated that, under realistic 
scenarios, common disease alleles would become associated at p<5x10
-8
 with disease-related 
traits through IEB alone, if disease prevalence in the sample differs appreciably from the 
background population prevalence. For example, some hypertension and type 2 diabetes 
alleles will be associated with BMI in sample sizes of >500,000 if the prevalence of those 
diseases differs by >10% from the background population. In conclusion, IEB may result in 
false positive or negative genetic associations in very large studies stratified or strongly 
enriched for/against disease cases. 
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Introduction 
Genome wide association studies (GWAS) in increasingly large sample sizes have resulted in 
the identification of many 1000s of genetic variants associated with various common 
diseases(1-3). We assume that the results from GWAS are robust to potential confounding 
factors because genetic variants are inherited randomly and not influenced by disease 
processes throughout life. These assumptions tend to hold provided population substructure is 
accounted for using standard methods(4-6). Researchers may also run genetic association 
studies in stratified samples (1, 2) to reduce the non-genetic variation in the trait and improve 
statistical power to detect variants not acting through a disease mechanism. However, 
performing an association test between a genetic variant and a continuous trait in a sample 
that is stratified, depleted or enriched for a disease outcome (collider) that is associated with 
both the genetic variant and the trait can result in paradoxical observations (Figure 1). Such 
bias is termed index event bias (IEB) or collider-stratification bias(7).  
An example of an index event biased association is that between type 2 diabetes risk alleles 
and lower BMI observed within diabetes case or control strata(8-10). In these examples the 
strata are enriched (type 2 diabetes cases) or depleted (type 2 diabetes controls) by disease 
status. Bias occurs because non-diabetic individuals with a diabetes protective allele are able 
to remain normo-glycaemic at higher BMIs than individuals without the protective allele, 
whilst individuals with a risk allele will tend to develop diabetes at lower BMIs compared to 
those without the risk allele. Considering this type of bias is very important because many 
large meta-analytic studies often perform GWAS analyses of traits in samples stratified by, 
enriched or depleted for disease status. Such bias can have different impacts on genetic 
associations and their interpretation, for example (a) in the case of true (positive) pleiotropy, 
the effect of the gene variant on the trait may be masked/reduced by IEB (false negative 
 at U
niversity of Exeter on January 11, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
  
finding); (b) in the case of no pleiotropy, a false (and often counterintuitive) association 
between gene variant and trait can be observed (false positive finding); (c) using a genetic 
variant as an instrumental variable in a Mendelian randomization analysis could result in 
false inferences about causal relationships between the disease and a correlated trait if 
estimates of that variants’ effects on the trait are biased.  
A research area closely related to IEB is secondary trait analysis in case-control sample 
design. Several approaches have been proposed in these settings to estimate the true effect 
between a risk factor and a genetic variant in the general population sample(11-16). Most of 
these methods yield unbiased estimators that are robust to model misspecifications and work 
for a wide range of noise distributions. In this paper we applied a retrospective likelihood 
maximization method (16), implemented in the R package SPREG, to correct for IEB for real 
data. Note, however, these methods provide only effect size estimation, but no insight how 
the bias explicitly depends on parameters such as (a) the extent of case-enrichment/depletion; 
(b) the strength of associations between the SNP, the risk factor and the collider; and (c) 
SNPs’ allele frequency.  
In this study, we tested the extent to which large genetic association studies may be impacted 
by IEB due to inadvertent sample selection leading to enrichment or depletion of disease 
cases. We first provided the statistical framework for quantifying IEB in a study, then used a 
combination of real and simulated data to: (a) identify and quantify real examples of IEB, 
including a single large study (120,000 individuals from the UK Biobank) and a meta-
analysis of independent studies and (b) demonstrate that IEBs can occur in most types of 
genetic association study designs, e.g. 1:1 case-control designs to case only and control only 
studies, case or control enriched studies and when case status is used as a covariate. The 
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analytical formula is implemented in an R package and available for download from 
http://wp.unil.ch/sgg/files/2016/01/IndexEventBias.zip.  
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Material and Methods  
Model formulation 
We assumed a liability scale disease (probit) model, where a genetic variant ( ) and a 
continuous risk factor () linearly influences the development of a disease (Y) on the liability 
scale. For simplicity the genetic marker was modeled by a binomially distributed random 
variable 	~	(2, 	), where 	 is the allele frequency of the genetic variant in the general 
population. The second trait, from now on referred to as the “continuous risk factor” () was 
allowed to be linearly associated with  and assumed to follow a normal distribution	(	| =
)~	(( − 2	), 1 − 2	(1 − 	)) . In other words,  = 	( − 2	) + 	 , where   is 
normally distributed with variance 1 − 2	(1 − 	). The disease status is then modeled as 
 =  1		 > 	0			 ≤ 	 	where	 = 	Φ$%	(1 − &) 
with 
(| = ',  = )	~	(( ∗ ' + 	* ∗ ( − 2	), +), 
where & is the disease prevalence in the general population; ( is the true effect size on the 
liability scale of the continuous risk factor () on the disease outcome (); * is the (risk-
factor independent) effect of the genetic variant () on the disease outcome (); and + =
1 −	( −	2*	(1 − 	).  
Link between liability scale and logistic models 
For simplicity, we derived the explicit analytical formula for IEB estimation for the liability 
scale model. This however does not prevent its applicability to parameters derived from the 
logistic regression model. By re-parameterizing the models one can reach indistinguishable 
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properties(17). Namely, we calculate the probability of (Y=0 | X, G) for data simulated from 
the logistic model and optimize the liability scale model parameters such that this probability 
is matched as close as possible for each simulated data point. We noticed that the models are 
indistinguishable when the parameter optimization is done for a simulated population with 
similar disease prevalence to the tested sample. The details of this procedure are given in the 
Appendix (section 2.3). 
Analytical formula for IEB 
The extent of IEB can be analytically derived in the case of the liability scale (probit) disease 
model. Assume that disease frequency in the general population is &, the allele frequencies 
of the genotype in pure control and pure case populations are 	 and 	%, respectively. We 
denote the difference between these frequencies by ,-. Let us consider now a sample with & 
frequency of cases.  The allele frequency in this sample is  
	. = 		 + 	& ∗ (	% 	− 		) = 	 	+ 	& ∗ ,- 
IEB occurs when this disease prevalence differs from the general population prevalence (&). 
When & > &, we observe an enrichment of cases, while in case of & < &, we observe an 
enrichment of controls. In the Supplementary Text we derived the per-allele linear regression 
effect size of G on X in the general case, but here for simplicity we present the formula 
assuming  = 0, i.e. that the true underlying effect of the genotype on the risk factor is zero. 
We observed that this simplification makes very little difference in practice (Supplementary 
Figure 1). By introducing the quantities 
+0|1 = 1	 − 	2*	(1 − 	) 
23 = 	 − *(4 − 2	)+0|1 	 
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we can express the expectation of the linear regression effect size estimate of  on  as  
56.78 ≈ (2	:(1 − 	:) .
: − &&(1 − &) <
2	(1 − 	)=(2%) + 2	=(2) − 2=()(:,- + 	)+0|1 > 
where =()  denotes the probability density function (pdf) of the standard Gaussian 
distribution. Note that when the disease prevalence matches the general population 
prevalence (i.e. & = &), the expected effect of  on  is unbiased. The formula also shows 
that the bias is a ratio of two expressions quadratic in the prevalence (&). For most settings 
the quadratic and linear terms of the denominator are small compared to that of the 
numerator, thus the bias as a function of the fraction of cases (&) closely resembles a simple 
parabolic function. It is worth noting that the coefficient of the quadratic term (in &) in the 
numerator ?− @(AB)CDEF|G	.B(%$.B)(H has the opposite sign compared to (, meaning that when  is a 
risk factor for the disease the function is a downward looking parabola. This explains why 
disease risk alleles can show spurious (and counterintuitive) protective effect on traits 
positively correlated with the disease. We also derived a formula for the case when we do not 
assume that the true effect is zero; i.e. when there is a true pleiotropy. The full derivation of 
the formula can be found in the Appendix (Section 2). 
Note that this formula assumes that the true parameters, (, *, 	, 	%, 	, & are known. Hence, 
its primary purpose is not to estimate the bias from data, but to reveal the intricate 
relationship between the true underlying model parameters and the resulting IEB. 
We extended the formula to situations when not only the sample is enriched or depleted for a 
disease, but also when in addition the continuous risk factor is corrected for the disease 
status: 
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56.7(I)8 =
.	.(1 − 	.) − ,-	(	=() &(1 − &)&(1 − &)	.(1 − 	.) − 	2	&(1 − &),-  
The full derivation of this formula is given in the Appendix (Section 3). One can observe that 
correcting for disease status yields biased estimates even when the study disease prevalence 
agrees with the general population prevalence. In this situation we showed that this formula 
simplifies to that of Aschard(18). 
These analytical formulae for IEB allow us to quantify genetic effects (estimated from real 
data) for IEB. The key quantities necessary for the formulae are: (i) the allele frequency of 
the genetic variant in control (q0) and disease (q1) populations; (ii) the association effect of 
the SNP on the disease status (β); (iii) the effect of the continuous risk factor on the disease 
status (α); (iv) the disease prevalence in the study population (π) and (v) the general 
population disease prevalence (π0). Estimating these quantities is out of the scope of this 
paper. We use the formula to show the extent of the bias for various realistic parameter 
settings informed from large GWAS data. 
Data simulation to confirm the analytical formula 
To investigate how closely the analytical formula recapitulates true IEB, we simulated data to 
create different hypothetical scenarios similar to data used in genetic studies 
(Supplementary Figure 2). We simulated binomially distributed SNP data (G), a normally 
distributed continuous risk factor (X) and binary disease status using the liability threshold 
model described above.  The minor allele frequency (MAF) of the genetic marker was 
explored in the range of 0.02, 0.05, 0.1, 0.3 and 0.5; disease prevalence in the general 
population was set to 1%, 5% and 10%. The effect of the continuous risk factor () on the 
disease outcome () was varied in a range equivalent to ORs of 1.10 to 4 (1.10, 1.25, 1.50, 
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1.75, 2, 3 and 4) per 1 standard deviation (SD) increase in . The effect (*) of the genetic 
variant () on the disease outcome () was explored for a range equivalent to odds ratios 
(OR) of 1.05, 1.2, 1.3, 1.5, 1.8 and 2. We simulated 101 settings with 100,000 total samples, 
for case-control ratios ranging from 0 to 100%. 
 
IEB in real data  
To identify and quantify real examples of IEB, we tested how IEB occurs in genetic studies 
in 2 different scenarios using different disease outcomes and genetic variants. 
(1) We tested whether or not type 2 diabetes risk alleles, acting predominantly through 
insulin secretion, have a paradoxical (opposite association) effect on BMI, a strong 
continuous risk factor for type 2 diabetes. We selected 11 SNPs associated with type 2 
diabetes that have known robust associations with insulin secretion (19), the intermediate trait 
most relevant to diabetes risk (19) (Supplementary Table 1). On purpose we avoided the use 
of insulin resistance variants, which could operate through adiposity. We analysed the 11 
SNPs separately and as a genetic risk score (GRS) in two study types: (i) a single very large 
population based study: 120,286 individuals from the first release of genetic data from the 
UK Biobank study(20) and (ii) a meta-analysis of 4 independent studies: EXTEND(21) (N = 
5,097), GoDARTS(22) (N = 7,128), Generation Scotland Scottish Family Health Study 
(GS:SFHS)(23)  (N = 8,195) and ARIC(24) (N = 9,324) with a range of study designs and 
diabetes status available (Supplementary Table 2). We tested the association between 
individual SNPs and the 11-SNP insulin secretion GRS and BMI in all samples, in all 
samples adjusted for type 2 diabetes status, in diabetic cases only and in controls only. We 
defined type 2 diabetes cases as individuals who had: (1) HbA1c >6.4% and/or fasting 
glucose >7 mmol/L, (2) age at diagnosis >35 and <70 years; (3) no need for insulin treatment 
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within 1 year of diagnosis (except in ARIC). We defined controls as individuals who did not 
meet any of these criteria and were not diagnosed with any other types of diabetes. We 
additionally tested the association between the CCND2 type 2 diabetes protective allele and 
BMI as the allele was recently shown to be associated with higher BMI. 
(2) We tested whether or not 29 SNPs robustly associated with systolic blood pressure have a 
paradoxical (opposite) effect on BMI, a continuous risk factor for high blood pressure(25). 26 
of the 29 variants were reliably imputed in the UK Biobank and we excluded the variant near 
SLC39A8 from the GRS as this variant is directly associated with several traits including 
BMI(26) and HDL-cholesterol(27) levels (Supplementary Table 3). We analysed the 
remaining 25 SNPs individually and as a GRS in two study types: (i) a single very large 
study: 120,286 individuals from the first release of genetic data from the UK Biobank 
study(20) and (ii) a meta-analysis of 4 independent studies with blood pressure available: 
GoDARTS(22) (N = 6643), Generation Scotland Scottish Family Health Study 
(GS:SFHS)(23)  (N = 8195), ARIC(24) (N= 9,290) and BRIGHT(28) (N = 1808) 
(Supplementary Table 2).  We tested the association between the individual SNPs and the 
25-SNP blood pressure GRS and BMI in all samples, in all samples adjusted for hypertension 
status, in hypertensive cases only and in normotensive controls only. We defined 
hypertensive cases as individuals with systolic blood pressure ≥ 140 mmHg or diastolic blood 
pressure ≥ 90 mmHg or report use of anti-hypertensive medications. We defined 
normotensive controls as individuals with systolic and diastolic blood pressure below these 
thresholds, and not on medications. 
Statistical analysis in real data 
In the relevant studies, we corrected BMI for age and sex and other covariates (for the UK 
Biobank study this included five within UK genetic principal components, genotyping 
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platform, study center in the UK Biobank study). Residuals were inverse-normal transformed. 
In each study, we generated genetic risk scores (GRS) by calculating the number of disease 
risk alleles carried by each individual. We then combined the association results using fixed-
effects inverse variance-weighted meta-analysis. To account for IEB we applied the state-of-
the-art method of Lin and Zeng(16) (implemented in the software SPREG).  This program 
needs an estimate of the general population prevalence of the examined diseases. Hence, we 
derived an estimate for type 2 diabetes and hypertension prevalence for a general UK sub-
population that has the same joint age- and sex-distribution as the UK Biobank sample. For 
this we used sex- and age-group-specific prevalence values from the IDF Atlas (29) (10 year 
bins) for type 2 diabetes and from the NIH Health Survey for England 2011 
[http://digital.nhs.uk/catalogue/PUB09300/HSE2011-Ch3-Hypertension.pdf] (10 year bins) 
for hypertension. We then weighted these prevalence values with the proportion of UK 
Biobank participants that fell into each stratum. This yielded prevalence estimates of 10.15% 
for type 2 diabetes and 38.43% for hypertension. 
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Results  
IEB occurs in a range of different genetic association study designs – theory and simulated 
data. 
Our results from simulated data and theory provided examples of IEBs where the direction of 
the association between the genetic risk allele and the risk factor depends on the proportion of 
cases and controls in the study. In all scenarios involving a disease risk allele with no real 
association to the intermediate risk factor, we observed U-shaped artefactual effect estimates 
between the disease risk allele and the risk factor as the proportion of cases moved from 0% 
to 100%: first, in a control only situation, IEB occurred where the disease risk alleles were 
associated with lower values of the risk factor, there was then no association when the 
proportion of cases represented exactly the background population, then an association 
between disease risk alleles and higher values of the risk factor, and then back to no 
association and finally an association between disease risk alleles and lower values of the risk 
factor in case only scenarios (Figure 2 [our theoretical formula]; Supplementary Figure 3 
[simulated data]). The extent of the bias is stronger in case only compared to control only 
scenarios when the disease frequency is less than 50% (as with most diseases). In the 
examples in Figure 2 (and Supplementary Figure 3), we modeled a disease risk allele and a 
protective allele with properties similar to those of the type 2 diabetes alleles at TCF7L2 and 
CCND2 respectively. We observed spurious associations between the disease alleles and 
lower and higher values of the continuous risk factor, depending on the proportion of cases 
and despite the lack of a genuine association between the genetic risk allele and the risk 
factor. When the examined study population matches the underlying general population in 
terms of disease prevalence (5% in case of our example), no bias is observed (Figure 2). It 
has been shown that for many scenarios a simple regression including the disease status as 
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covariate alleviates the bias(15), but such correction is clearly of no use in case-only, and 
control-only designs and it introduces bias even for samples representative of the general 
population. Note that in our settings the bias was not resolved, but often exacerbated by 
correcting for disease status (Figure 2). 
Differences in prevalence for Type 2 diabetes and hypertension in the UK Biobank and 
general UK population 
Index event bias arises due to differences in the (collider) disease prevalence in the study 
population and the matched general population. Hence, it is crucial to derived accurate 
estimates for type 2 diabetes and hypertension prevalence for a general UK sub-population 
that has the same joint age- and sex-distribution as the UK Biobank. Using data from the IDF 
Atlas (29) and the NIH Health Survey for England, we estimated that  10.15% and 38.43% of 
a sex- and age-matched sub-population of the UK would be diabetic and hypertensive, 
respectively (see Methods). These values clearly differ from the prevalence of type 2 diabetes 
(3.4%) and hypertension (55.2%) observed in the UK Biobank. 
Individual alleles and genetic risk scores associated with higher risk of type 2 diabetes were 
associated with lower BMI in real data 
A relatively high ability to secrete insulin may lead to a relative protection from type 2 
diabetes but may also lead to higher BMI because insulin has anabolic properties. Studies 
may therefore wish to use common variants associated with insulin secretion to test the role 
of insulin secretion on BMI. However, there may be a complex relationship because higher 
BMI increases diabetes risk. IEB will add to the complexity of interpreting potential overlap 
of genetic associations for these phenotypes.  We tested 11 variants associated with type 2 
diabetes through an insulin secretion mechanism, for potentially spurious associations with 
lower levels of the continuous risk factor for type 2 diabetes, BMI. Details of how these 
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variants were associated with type 2 diabetes in UK Biobank and 4 additional studies are 
given in Supplementary Table 4. Using a total of 4,003 type 2 diabetes cases and 113,203 
controls from the UK Biobank, two of the 11 variants were associated with lower BMI in all 
individuals (unstratified and unadjusted), three in controls only, three in cases only and five 
in all individuals when adjusted for type 2 diabetes status at p<0.05 (Table 1). When meta-
analysing the UK Biobank and four additional studies in the same analysis design as a 
GWAS meta-analysis (all individuals together for population based studies, stratified by case 
control status for case control studies) two type 2 diabetes risk alleles were associated at 
p<0.05 with lower BMI (Supplementary Table 5). In the UK Biobank study, the effect sizes 
of type 2 diabetes risk alleles with lower BMI were consistent with IEB (Supplementary 
Figure 4). In accordance with our formula, BMI “effect” size estimates were correlated with 
the effect estimates for type 2 diabetes; r = -0.85 (p=8E-4), -0.87 (p=4E-4) and -0.87 (p=5E-
4) in controls, cases and all individuals (adjusted for type 2 diabetes status), respectively 
(Supplementary Figure 4).  
We next reran the SNP-BMI associations, using a retrospective likelihood based method 
implemented in the statistical software SPREG, which accounts for IEB(16). Prior to this 
correction, the risk allele at TCF7L2 was associated with lower BMI in all scenarios (the 
overall population as well as stratified and corrected data - Table 1). After correcting for IEB 
there was no evidence (at p<0.005; p-value corrected for multiple testing) for an association 
between TCF7L2 and lower BMI (Table 1). In contrast, the type 2 diabetes risk allele at 
MTNR1B was the only allele associated with higher BMI in the overall population (p = 0.02); 
when accounting for IEB it was even more strongly associated (0.016 SD [0.007, 0.026], 
P=0.001) (Table 1, Figure 3). The type 2 diabetes protective allele in CCND2 (conferring the 
strongest effect on type 2 diabetes; 0.59 OR [0.48,0.73]; p = 1E-6) had the strongest effect 
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estimate on BMI (0.06 SD [0.03,0.09]; p = 0.0004), which became much weaker after 
correcting for IEB (0.003 SD [-0.029,0.035]; p = 0.9).  
We next examined a genetic risk score (GRS) for type 2 diabetes. Details of how this GRS 
was associated with type 2 diabetes are given in Supplementary Table 4. In the UK Biobank 
study, the 11-SNP GRS was not associated with BMI when analysed in all samples combined 
(-0.004 SD per allele [-0.010,0.001]; p=0.1; N=119,688; Table 2). In contrast, the 11-SNP 
GRS associated with higher risk of type 2 diabetes was associated with lower BMI in all 3 of 
the following designs: (i) controls only (-0.010 SD per allele [-0.016,-0.005]; p=5E-4; 
N=113,203), (ii) in cases only (-0.036 SD per allele [-0.065,-0.007]; p=0.01; N=4,003) and 
(iii) in all individuals when adjusted for type 2 diabetes status (-0.011 SD per allele [-0.017,-
0.006]; p=1E-4; N=117,206; Table 2). In the context of a Mendelian randomization analysis, 
these results could be misinterpreted as evidence for the biologically plausible hypothesis that 
lower insulin secretion leads to lower BMI. However the associations are consistent with 
IEB. Results from a meta-analysis of 4 additional studies (representing a scenario similar to 
that of many GWAS meta-analyses) were similar (Table 2 and Figure 4a).  
Individual alleles and genetic risk scores associated with higher risk of hypertension were 
associated with lower BMI  
We next tested whether alleles associated with higher risk of hypertension were paradoxically 
associated with lower BMI, a continuous risk factor for hypertension, but with a weaker 
effect than that with type 2 diabetes. Such associations could be due to genuine pleiotropic 
effects of alleles on hypertension and lower BMI, or due to IEB, or a combination of the two. 
We tested 25 variants associated with blood pressure. Details of how these variants were 
associated with hypertension in UK Biobank and four additional studies are given in 
Supplementary Table 6. Using a total of 65,584 hypertension cases and 53,377 controls 
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from the UK Biobank, six of the 25 variants were associated with lower BMI in all 
individuals (unstratified and unadjusted), 10 in controls only, 10 in cases only and 12 in all 
individuals when adjusted for hypertension status (at p<0.05; Table 3). When meta-analysing 
the UK Biobank and four additional studies, in the same analysis design as a GWAS meta-
analysis (all individuals together for population based studies, stratified by case control status 
for case control studies), eight hypertension risk alleles were associated at p<0.05 with lower 
BMI (Supplementary Table 7). The effect sizes of hypertension risk alleles with lower BMI 
were consistent with IEB. As with type 2 diabetes alleles, BMI “effect” sizes were correlated 
with the effect size on hypertension: r = -0.38 (p=0.06), -0.58 (p=0.002) and -0.55 (p=0.005) 
in controls, cases and all individuals (adjusted for hypertension status), respectively 
(Supplementary Figure 5).  
Using SPREG, out of the 25 hypertension SNPs only CYP17A1 was associated with lower 
BMI in the IEB corrected analysis (-0.028 [-0.044,-0.012]; P=3E-4) and Bonferroni 
correction for the number of SNPs tested (Table 3). Five other variants (those in or near 
BAT2, CACNB2 (2 variants), CYP1A1, and SH2B3) were associated with lower BMI at 
p<0.05 but did not persist after Bonferroni correction. Nevertheless, six variants reaching 
IEB-corrected nominally significant P-values is more than the ~1 expected by chance 
(enrichment P = 1.69E-4) and suggests variants in some of these genes have pleiotropic 
effects with alleles associated with lower BMI and higher risk of hypertension. Consistent 
with this evidence of pleiotropy, the variant in SH2B3 is associated with multiple traits 
including those related to autoimmunity as well as metabolic traits(30-32).  
We next considered a genetic risk score of hypertension SNPs. Details of how this GRS was 
associated with hypertension are given in Supplementary Table 6). In the UK Biobank 
study, the 25-SNP hypertension GRS was associated with lower BMI in all samples 
 at U
niversity of Exeter on January 11, 2017
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
  
combined (-0.014 SD per allele [-0.020,-0.008]; p=1E-6; N=119,688) and in all 3 of the 
following designs: (i) in controls only (-0.034 SD per allele [-0.043,-0.026]; p=2E-16; 
N=53,377), in cases only (-0.031 SD per allele [-0.039,-0.024]; p=4E-16; N=65,584) and in 
all samples when adjusted for hypertension status (-0.033 SD per allele [-0.038,-0.027]; 
p=7E-31; N=118,961; Table 2). Results from a meta-analysis of 4 studies (representing a 
GWAS meta-analysis) were similar (Table 2 and Figure 4b). 
Large sample sizes are necessary to observe false positive associations due to IEB 
Our analytical formula enabled us to quantify the necessary sample size in order to observe a 
false positive association with a continuous risk factor due to IEB at any significance level 
alpha with for example, 80% power. The necessary sample size depends on five parameters: 
significance level, disease prevalence, strength of association between the genetic risk factor 
and the disease, strength of association between the continuous risk factor and the disease and 
frequency of the genetic risk allele. We fixed the continuous risk factor-disease association 
(OR=2.5 per SD) and tested two MAF scenarios (low, 2% and medium 30%) and two 
significance levels (0.05 and 5E-8). The remaining two parameters (SNP-disease association 
strength and disease prevalence) we varied freely and computed the minimal sample size 
necessary to detect a false association (Figure 5). For example, in analyses stratified by 
disease we would need 23,542 cases or 208,267 controls to detect a biased association at p-
value 5x10
-8
 with a probability of 80% when the disease risk allele had a frequency of 30%, 
the disease prevalence was 10% and a 1 SD higher value of the continuous risk factor was 
associated with an odds ratio of 2.5 for the disease. This scenario is similar to that for the risk 
allele at TCF7L2 and BMI(10). Notably, scenarios with SNP-disease OR=1.2 in 500,000 
disease-free samples will yield (with 80% probability) false positive genome-wide significant 
SNP-risk factor association entirely due to IEB.  
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Discussion  
Our analyses of real and simulated data showed that index event bias will often occur in 
genetic association studies but the extent depends on several factors. These factors include 
the association strength between the trait being analysed (that we termed the “continuous risk 
factor”) and the disease, where the disease is over- or under-represented in the study 
population compared to the background population. The other factors are disease prevalence, 
sample size, and the effect size and minor allele frequency of the disease associated variant. 
Our results go beyond those of previous studies examining index event biases in several 
ways. First we provide real examples of likely biased genetic associations in the context of 
studies of 100,000s of individuals, including those involving individual variants and 
combinations of variants. Second, we provide a formula for quantifying the bias as a function 
of key parameters even when only summary level data is provided. We also extended the 
work of Aschard et al(18), to test how the combination of correcting for disease status in 
disease-enriched or depleted samples can introduce biases. 
Our results have important implications for all types of large genetic association studies, and 
are especially relevant given that analyses are now possible in 100,000s of individuals, and 
rarely will these samples be perfectly representative of the background populations – for 
example, even population based studies such as those of Decode, 23andMe and the UK 
Biobank are likely not truly representative of the background population in the prevalence of 
all disease outcomes. Our analyses of real and simulated data showed that the best study 
design to avoid index event biased associations is using all individuals from a population-
based study with no adjustment for disease status. Bias is strongest in case only designs 
(assuming the disease frequency is <50%) but it is also observed in control only designs, or in 
analysis combining cases and controls and adjusting for disease status (the latter situation is 
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discussed in Aschard et al(18)). To better understand these observations, we derived an 
analytical formula that estimates IEB and confirmed its validity through simulation studies. 
Our formula indicates that this bias can be negative or positive depending on the proportion 
of cases and controls. The results indicate that this bias cannot be resolved by correcting for 
disease status as a covariate. If anything, such correction exacerbates biased effect estimates. 
Our results also indicate that the impact of IEB is substantially larger than the bias caused by 
improper covariate correction in a disease-representative population (described by Aschard et 
al(18)). 
In a meta-analysis it may be difficult to assess the extent to which IEB is contributing to an 
association - most existing large scale genetic association studies are mixtures of all types of 
study designs, and, for studies of continuous traits (such as BMI, lipid levels or blood 
pressure) disease cases and controls are often analysed as separate strata before meta-analysis 
with population-based studies, which themselves could be over or under represented with 
disease cases.  
Our settings for the analytical formula were limited to a liability scale disease model and 
normal linear regression applied for the risk trait. By model re-parameterization we extended 
it to the logistic disease model and through simulations we saw that it works equally well 
(data not shown). These are the most often used models in meta-analytic GWAS studies; 
hence we believe that our findings are extremely relevant for almost all GWAS analysis. 
Whilst index event biases are likely to exist in many studies, for associations modelling 
individual variants the bias is unlikely to cause false positive or false negative associations 
unless sample sizes are very large or stratified, strongly depleted of, or enriched for, disease 
cases. For example, we tested known common type 2 diabetes variants for association with a 
strong risk factor for type 2 diabetes, BMI, in 119,688 UK Biobank individuals (including 
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4003 type 2 diabetes cases), but only the most strongly associated diabetes variant, that in 
TCF7L2 (odds ratio ~1.4), was associated with lower BMI at p<0.01 in all individuals. The 
association between the variant in TCF7L2 and BMI has been the subject of several previous 
papers(1, 8, 33) and was most recently noted as showing stronger effect estimates in case 
control studies(1). Here we found only a trend, but no clear statistical evidence that the 
TCF7L2 variant is associated with BMI - the associations we did see could be explained by 
IEB due to a likely depletion of cases in the UK Biobank study compared to the background 
population.  
The derived analytical formula can serve as guidance for the expected bias in genome-wide 
association studies, where only summary level data is known where – to our knowledge – no 
other method is applicable. The state-of-the-art tool, SPREG, computed the corrected effect 
in ~2 min per SNP, which renders such methods infeasible for large population cohorts with 
genome-wide genotype data, as it would take >10 CPU years to apply for millions of 
markers.   
Accounting for IEB strengthened associations for several individual variants with good prior 
evidence for pleiotropic effects on the disease and continuous risk factor. For example, the 
type 2 diabetes risk allele at MTN1RB was associated in the UK Biobank with higher BMI 
and this result strengthened on correction for IEB – results from previous studies, particularly 
those that were not population-based, may have been biased towards the null. This variant has 
one of the strongest effects on fasting glucose levels in individuals without diabetes and may 
predispose to higher BMI through higher insulin secretion. The hypertension risk allele at 
CYP17A1 was previously associated with lower BMI(1), and we show here that this is a 
likely pleiotropic effect.  
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Studies examining the joint effect of multiple variants will be more prone to index event 
biases than those of single variants. Studies prone to miss-interpretation could include gene-
based tests, and tests of the cumulative effect of variants when using a genetic risk score. For 
example, Mendelian randomization studies often use genetic risk scores as instruments to test 
causality of an associated trait with a disease(34-37). Stratified Mendelian randomization is 
recommended when the exposure is binary (e.g. smoking) and hence a causal effect should be 
seen only in the exposed stratum(38). Such stratification in some cases could introduce IEB 
in the causal estimation(38). Failing to account for IEB could lead to false conclusions about 
causality. We explored this potential source of bias using the UK Biobank to assess whether 
or not a genetic risk score of insulin secretion (represented by 11 variants associated with 
type 2 diabetes through insulin secretion mechanisms) was associated with BMI. An 
association between a genetic risk score for poorer insulin secretion and lower BMI could 
indicate that insulin secretion causally alters BMI, a plausible hypothesis given that insulin 
treatment increases BMI in diabetes(39). However, IEB would also result in an association 
between a genetic risk score for poorer insulin secretion (type 2 diabetes risk alleles) and 
lower BMI. Whilst we cannot disentangle IEB from a genuine pleiotropic effect IEB is the 
more likely explanation given the gradient of stronger effects in cases compared to controls 
compared to all individuals (Supplementary Figure 6a). Similar analysis for hypertension 
provided evidence that SNPs associated with higher blood pressure are also associated with 
lower BMI (Supplementary Figure 6b).  
In summary, as genetic association studies reach sizes of 100,000s of individuals, analyses 
will be prone to misinterpreting results if they do not account for index event biases. 
However, we have provided the statistical framework and its software implementation for 
quantifying and correcting for these biases under reasonable assumptions. Because IEB is 
dependent on many different factors it may occur in a variety of situations and can cause false 
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positive and false negative results. Researchers should be particularly vigilant when either or 
all of the following occur: i) a known disease variant is associated with a known risk factor 
for that disease, ii) the association is in the opposite direction to that seen observationally 
between disease and risk factor, iii) the sample size or effect size of the allele on the disease 
are particularly large. As a rule of thumb, we suggest that, for single variants, people should 
take extra care when disease odds ratios are >1.4 and sample sizes are >100,000.  
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Tables  
Table 1. Association between 11 insulin secretion SNPs and BMI (SD) in the UK Biobank study under 5 scenarios. Corrected statistics are 
those after correcting for index event bias using all 119,688 individuals. Note that the numbers of individuals in the “all” analyses differ slightly 
because people of uncertain diabetes diagnosis were excluded from the “All adjusted for type 2 diabetes” analysis. 
 
All  
(N=119,688) 
Controls  
(N=113,203) 
Cases  
(N=4,003) 
All adjusted for type 
2 diabetes 
(N=117,206) 
All - Corrected 
statistics 
(N=119,688) 
Variant in or 
near gene: 
BETA P BETA P BETA P BETA P BETA P 
TCF7L2 -0.024 1E-7 -0.033 8E-13 -0.118 1E-7 -0.036 1E-15 -0.0101 0.04 
THADA -0.011 0.1 -0.012 0.08 -0.060 0.1 -0.013 0.05 -0.0020 0.8 
CDKN2AB -0.008 0.2 -0.014 0.01 -0.018 0.5 -0.014 0.009 -0.0013 0.8 
SLC30A8 -0.005 0.3 -0.009 0.05 -0.034 0.2 -0.009 0.03 -0.0008 0.9 
CDKAL1 -0.012 0.01 -0.016 5E-4 -0.048 0.03 -0.018 1E-4 -0.0062 0.2 
MTNR1B 0.011 0.02 0.008 0.08 0.004 0.9 0.008 0.08 0.0162 0.001 
HHEX -0.005 0.2 -0.007 0.09 -0.054 0.01 -0.009 0.04 0.0005 0.9 
GCK -0.005 0.3 -0.009 0.1 -0.009 0.7 -0.009 0.1 -0.0005 0.9 
PROX1 -0.001 0.8 -0.002 0.6 -0.002 0.9 -0.002 0.6 0.0023 0.6 
ADCY5 -0.002 0.7 -0.006 0.2 0.012 0.6 -0.005 0.3 -0.0014 0.8 
DGKB -0.003 0.5 -0.005 0.2 -0.008 0.7 -0.005 0.2 0.0021 0.6 
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Table 2. Examples of index event bias observed in real data when using multiple variants in genetic risk scores. BMI was inverse-normal 
transformed.  
  UK Biobank study Meta-analysis of independent studies 
Model Samples BETA LCI UCI P N BETA LCI UCI P N 
BMI ~ insulin 
secretion GRS 
All individuals -0.004 -0.010 0.001 0.14 119,688 0.001 -0.010 0.013 0.8 30,440 
Type 2 diabetes controls -0.010 -0.016 -0.005 5E-4 113,203 -0.008 -0.019 0.004 0.2 25,039 
Type 2 diabetes cases -0.036 -0.065 -0.007 0.015 4,003 -0.037 -0.062 -0.012 0.004 5,396 
All individuals adjusted for 
type 2 diabetes status 
-0.011 -0.017 -0.006 1E-4 117,206 -0.013 -0.021 -0.005 0.002 30,435 
BMI ~ blood pressure 
GRS 
All individuals -0.014 -0.020 -0.008 1E-6 119,688 -0.008 -0.020 0.004 0.2 25,059 
Normotensive controls -0.034 -0.043 -0.026 2E-16 53,377 -0.014 -0.028 0.000 0.06 18,590 
Hypertensive cases -0.031 -0.039 -0.024 4E-16 65,584 -0.042 -0.063 -0.021 9E-5 8,267 
All individuals adjusted for 
hypertension status 
-0.033 -0.038 -0.027 7E-31 118,961 -0.022 -0.034 -0.010 4E-4 25,049 
50
51
52
53
54
55
56
57
58
59
60
 at University of Exeter on January 11, 2017 http://hmg.oxfordjournals.org/ Downloaded from 
  
Table 3. Association between 25 blood pressure SNPs and BMI (SD) in the UK Biobank study 
under 5 scenarios. Corrected statistics are those after correcting for index event bias using all 
119,688 individuals. Note that the numbers of individuals in the “all” analyses differ slightly 
because people of uncertain hypertension diagnosis were excluded from the “All adjusted for 
hypertension” analysis. 
 
All 
(N=119,688) 
Controls  
(N= 53,377) 
Cases 
(N=65,584) 
All adjusted for 
hypertension 
(N=118,961) 
All - Corrected 
statistics 
(N=119,688) 
Variant in or 
near gene: 
BETA P BETA P BETA P BETA P BETA P 
ADM 0.001 0.9 0.005 0.6 -0.012 0.1 -0.005 0.4 0.0009 0.9 
ATP2B1 -0.002 0.7 -0.012 0.1 -0.011 0.1 -0.012 0.03 -0.0038 0.5 
BAT2 -0.013 2E-3 -0.014 0.02 -0.016 3E-3 -0.015 2E-4 -0.0135 0.002 
C10orf107 -0.008 0.1 -0.012 0.1 -0.019 9E-3 -0.016 3E-3 -0.0095 0.08 
CACNB2(3’) -0.01 0.03 -0.02 1E-3 -0.013 0.02 -0.016 1E-4 -0.0100 0.02 
CACNB2(5’) -0.012 4E-3 -0.023 1E-4 -0.01 0.06 -0.016 8E-5 -0.0122 0.003 
CYP17A1 -0.028 3E-4 -0.044 4E-5 -0.032 2E-3 -0.038 5E-7 -0.0282 0.0003 
CYP1A1 -0.011 0.01 -0.017 9E-3 -0.016 7E-3 -0.016 2E-4 -0.0110 0.01 
EBF1 -0.001 0.89 -0.012 0.04 -0.002 0.7 -0.007 0.1 -0.0008 0.9 
FGF5 -0.007 0.1 -0.023 4E-4 -0.014 0.01 -0.018 3E-5 -0.0078 0.08 
FLJ32810 -0.008 0.07 -0.014 0.03 -0.016 8E-3 -0.015 6E-4 -0.0084 0.07 
FURIN 0 0.98 -0.008 0.2 -0.008 0.2 -0.008 0.07 -0.0005 0.9 
GNAS -0.004 0.5 -0.007 0.5 -0.019 0.02 -0.014 0.02 -0.0042 0.5 
GOSR2 -0.001 0.8 -0.011 0.2 -0.003 0.7 -0.007 0.2 -0.0012 0.8 
HFE 0.002 0.8 -0.008 0.3 -0.001 0.9 -0.004 0.5 0.0026 0.6 
JAG1 0 0.95 -0.005 0.4 -0.002 0.8 -0.003 0.4 -0.0005 0.9 
MECOM 0.002 0.7 -0.006 0.3 0.001 0.9 -0.002 0.6 0.0016 0.7 
MOV10 0.007 0.1 0 0.97 0.007 0.3 0.004 0.4 0.0079 0.1 
MTHFR -0.011 0.05 -0.018 0.02 -0.024 1E-3 -0.021 7E-5 -0.0110 0.05 
NPR3 0.004 0.3 -0.001 0.9 -0.006 0.3 -0.004 0.4 0.0042 0.3 
PLCE1 -0.001 0.8 0 0.98 -0.009 0.1 -0.005 0.2 -0.0017 0.7 
PLEKHA7 -0.005 0.3 -0.016 0.01 0.002 0.8 -0.006 0.2 -0.0049 0.3 
SH2B3 -0.009 0.03 -0.008 0.2 -0.023 2E-5 -0.016 4E-5 -0.0093 0.02 
TBX5 -0.003 0.6 -0.004 0.6 -0.008 0.2 -0.006 0.2 -0.0031 0.5 
ZNF652 0.006 0.1 0 0.98 0.005 0.4 0.003 0.5 0.0063 0.1 
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Figures 
Figure 1. Apparently paradoxical gene-phenotype associations in the context of disease 
stratified genetic studies. We simulated genotype, continuous risk factor values and disease 
status in a general population sample according to our liability scale model and set the 
genetic effect on the risk factor () to zero. We observed that the estimated effect of the “B” 
allele of a genetic marker on a continuous trait is negative both in cases and controls. Disease 
carriers also have higher trait value than controls. However, when combining the two strata 
the marker is – as expected – not associated with the trait. The reason for this apparent 
paradox is that the proportion of disease risk allele (“B”) carriers is higher in the case group. 
Thus when merging cases into the control group the mean trait value of the BB group 
increases much more than it does in the other genotype groups. This concept is recognized as 
Simpson's paradox(41).  
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Figure 2. Enrichment for cases or controls produces spurious associations. We applied 
our analytical formula to compute the effect size estimate of a SNP (G) on a continuous risk 
factor (X) in the abovementioned liability scale model setting with the true genetic effect on 
the risk factor () being zero. Enrichment for cases or controls produces spurious evidence of 
association between disease risk alleles and a risk factor correlated with the disease 
(equivalent to 2.5 OR per SD) in (a) a scenario where a risk allele (MAF 30%) increases risk 
with an effect equivalent to an odds ratio of 1.4 (similar to the TCF7L2 type 2 diabetes 
scenario(10)) in two models: unadjusted for disease status [blue curve] and adjusted for 
disease status [green curve]. Dashed lines represent 95% confidence interval (CI) around the 
effect estimate assuming a population of 100,000 individuals. Panel (b) displays the same 
curves, but for a SNP with a rare protective allele (MAF 2%) that reduces risk of disease with 
an effect equivalent to an odds ratio of 0.5 (similar to the CCND2 type 2 diabetes 
scenario(9)). Vertical dashed red line at 0.05 indicates the true general population disease 
prevalence.  
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Figure 2b 
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Figure 3. Scatter plot of the observed effect of type 2 diabetes-associated SNPs on BMI 
in the total UK Biobank sample vs. the index event bias corrected effect. The effect 
corrected for index event bias (shown on the y-axis) was calculated assuming the previously 
established 10% population prevalence of type 2 diabetes (& = 0.10) . Dashed line 
represents the identity line, where the two effects are equal. While for most SNPs the 
absolute value effect size estimate after IEB correction is reduced, MTNR1B shows increased 
effect size upon correction. Only this latter SNP produced a P-value surviving multiple 
testing correction (P<0.05/11).  
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Figure 4. Index event bias in real data. (a) The genetic risk score (GRS) associated with 
higher risk of type 2 diabetes is associated with lower BMI in cases and controls separately 
and when combined but adjusted for type 2 diabetes status. (b) The GRS associated with 
higher risk of hypertension is associated with lower BMI in hypertensive cases and controls 
separately and when combined but adjusted for hypertension status. The x-axis is the effect 
size per disease risk allele. The vertical solid line is the null effect. 
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The effect of 1 SD increase in hypertension gene c risk score on BMI (SD) 
Figure 4b 
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Figure 5. Power calculation to detect IEB. Using the analytical formula for IEB we derived 
the minimal necessary sample size to observe IEB in a study at nominal (alpha=0.05, top 
panels) and genome-wide significant level (alpha = 5E-8, bottom panels) with 80% power. 
We fixed the disease prevalence in the general population to 10%. The SNP-disease odds 
ratio was varied between 1 and 2.3 and the observed population prevalence of the disease was 
explored for the full range of 0-100%. The SNP MAF was set to 30% in the left panels and to 
2% in right panel. 
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